drugset / Trial / NCT02255799

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week trial of donepezil 10 mg daily for verbal memory problems among adults with TBI in the subacute or chronic recovery period. The study will recruit 160 persons with TBI and functionally important memory problems during a four-year period of open recruitment. The study aims are: 1. To evaluate the effects of treatment with donepezil on verbal memory as assessed by the Hopkins Verbal Learning Test-Revised Total Trial 1-3; 2. To evaluate the effects of treatment with donepezil on memory-related activities as measured by the Everyday Memory Questionnaire; 3. To evaluate the effects of donepezil on attention, processing speed, neuropsychiatric symptoms, community participation, quality of life, and caregiver experiences.

Timeline

Start
2013-09-01
Primary completion
2024-12-04
Completion
2024-12-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 10 mg